文献速递神经肿瘤

新型脑渗透性共济失调毛细血管扩张突变抑制剂WSD0628对脑肿瘤患者来源异种移植瘤产生强效放射增敏作用

The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts.
PubMed 文献 · Neuro Oncol · 2025-01-01

研究在胶质母细胞瘤和脑转移患者来源异种移植模型中评估ATM抑制剂WSD0628的放射增敏作用。WSD0628联合放疗较对照或单放疗显著延长原位移植瘤中位生存期,并抑制放疗诱导信号、减少γH2AX焦点。结果提示WSD0628联合放疗在脑肿瘤中有前景,为正在进行的复发GBM 0/1A期临床试验提供依据。

要点

  • WSD0628为增强血脑屏障分布而设计,用于联合放疗治疗胶质母细胞瘤和脑转移。
  • WSD0628联合放疗较对照或单放疗延长多个原位PDX模型的中位生存期。
  • 联合治疗组肿瘤中WSD0628达抑制水平并减少γH2AX焦点。

核心结论

  • 结果提示WSD0628联合放疗在脑肿瘤中有前景,并为正在进行的复发GBM 0/1A期临床试验提供依据。

研究设计与样本

  • 使用小分子ATM激酶抑制剂WSD0628,在胶质母细胞瘤和脑转移患者来源异种移植模型中进行体外和体内研究。

主要发现

  • WSD0628在激酶家族间显示高选择性、有限的醛氧化酶相关风险和低hERG相互作用风险。
  • WSD0628阻断放疗诱导信号并增强U251胶质瘤细胞及脑肿瘤PDX GBM120和M12的放射敏感性。
  • 原位PDX中联合治疗较对照和单放疗的中位生存期:GBM12为19、55和408天;GBM43为26、44和143天;GBM120为51、89和231天;M12为17、39和190天。
  • 原位GBM43肿瘤治疗后药代/药效检测显示WSD0628达抑制水平,联合治疗组γH2AX焦点减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ataxia-telangiectasia mutated (ATM) protein coordinates the cellular response to therapeutic radiation, and ATM inhibitors can potentially enhance the efficacy of radiation in otherwise radiation-resistant tumors. METHODS: The small molecule ATM kinase inhibitor WSD0628 was specifically designed for enhanced distribution across the blood-brain barrier to more effectively treat glioblastoma (GBM) and brain metastases in combination with radiation therapy (RT). GBM and brain metastasis patient-derived xenograft models were used to understand target inhibition, radiosensitization, inhibition of the DNA damage response, and in vivo efficacy. RESULTS: Initial in vitro characterization of WSD0628 demonstrates a high level of selectivity across kinase families, limited aldehyde oxidase liability, and low risk of hERG interactions. Consistent with a central role for ATM in radiation response, WSD0628 blocked radiation-induced signaling and enhanced radiosensitivity in U251 glioma cells and brain tumor PDXs GBM120 and M12. In comparison to control or RT alone in orthotopic PDXs, the combination of WSD0628 with RT markedly prolonged median survival-GBM12 (19, 55, and 408 days, respectively); GBM43 (26, 44, and 143 days, respectively); GBM120 (51, 89, and 231 days, respectively); M12 (17, 39, and 190 days, respectively). Pharmacokinetic and pharmacodynamic testing after treatment in orthotopic GBM43 tumors showed inhibitory levels of WSD0628 and a reduction of γH2AX foci in the combination-treated tumors. CONCLUSIONS: Collectively, these results suggest a promising role for WSD0628 in combination with RT in brain tumors and provide the rationale for an ongoing Phase 0/1A clinical trial testing this combination in recurrent GBM.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Xue Z, Mladek AC, Rathi S, et al. The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts. Neuro Oncol. 2025. PMID: 40230030. doi:10.1093/neuonc/noaf102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。